Table 1.
Patient characteristics and non–PsO/PsA‐related comorbidities in moderate‐to‐severe PsO+PsA patients and matched controlsa
| Moderate‐to‐severe PsO+PsA patients (n = 1,230) | Controls (n = 1,230) | Unadjusted P (patients vs. controls)b | |
|---|---|---|---|
| Demographics | |||
| Age, mean ± SD years | 48.46 ± 10.75 | 48.46 ± 10.75 | – |
| Age group, years | |||
| 18–29 | 72 (5.9) | 72 (5.9) | – |
| 30–39 | 192 (15.6) | 192 (15.6) | – |
| 40–49 | 330 (26.8) | 330 (26.8) | – |
| 50–59 | 417 (33.9) | 417 (33.9) | – |
| 60–64 | 219 (17.8) | 219 (17.8) | – |
| Sex | |||
| Male | 641 (52.1) | 641 (52.1) | – |
| Female | 589 (47.9) | 589 (47.9) | – |
| Geographic region | |||
| Northeast | 260 (21.1) | 260 (21.1) | – |
| Midwest | 302 (24.6) | 302 (24.6) | – |
| South | 410 (33.3) | 410 (33.3) | – |
| West | 156 (12.7) | 156 (12.7) | – |
| Unknown | 102 (8.3) | 102 (8.3) | – |
| Health insurance type | 0.4075 | ||
| Preferred provider organization | 817 (66.4) | 788 (64.1) | |
| Point of service | 183 (14.9) | 198 (16.1) | |
| Indemnity | 191 (15.5) | 212 (17.2) | |
| Other | 39 (3.2) | 32 (2.6) | |
| Index year | |||
| 2007 | 134 (10.9) | 134 (10.9) | – |
| 2008 | 197 (16.0) | 197 (16.0) | – |
| 2009 | 288 (23.4) | 288 (23.4) | – |
| 2010 | 428 (34.8) | 428 (34.8) | – |
| 2011 | 183 (14.9) | 183 (14.9) | – |
| Modified CCI, mean ± SDc | 0.23 ± 0.81 | 0.12 ± 0.46 | < 0.0001d |
| Non–PsO/PsA‐related comorbidities | |||
| Dementia | 1 (0.1) | 3 (0.2) | 0.6250 |
| Lung diseasee | 117 (9.5) | 75 (6.1) | 0.0015d |
| Liver disease | 42 (3.4) | 12 (1.0) | < 0.0001d |
| Renal disease | 24 (2.0) | 16 (1.3) | 0.1944 |
| Peptic ulcer disease | 12 (1.0) | 4 (0.3) | 0.0768 |
| Rheumatic disease unrelated to PsO/PsAf | 14 (1.1) | 3 (0.2) | 0.0127g |
| Hemiplegia | 4 (0.3) | 2 (0.2) | 0.6875 |
| AIDS | 6 (0.5) | 2 (0.2) | 0.2891 |
Values are the number (percentage) unless indicated otherwise. Demographics were measured as of the index date; non–PsO/PsA‐related comorbidities were measured during the 12‐month study period. PsO = psoriasis; PsA = psoriatic arthritis; CCI = Charlson Comorbidity Index; AIDS = acquired immune deficiency syndrome.
Univariate comparison was made using Wilcoxon's signed rank tests for modified CCI, McNemar's tests for non–PsO/PsA‐related comorbidities (exact binomial distribution was used if the number of discordant pairs was ≤25), and chi‐square tests for health insurance type.
Calculated based on non–PsO/PsA‐related comorbidities using the methodology described by Romano et al 30.
Significance at 0.01 level.
Including cor pulmonale, pulmonary heart disease, chronic obstructive pulmonary disease, and asthma.
Excluding rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and Sjögren's syndrome.
Significance at 0.05 level.